Unknown

Dataset Information

0

Novel agents and immune invasion in Hodgkin lymphoma.


ABSTRACT: The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, these agents are currently being tested in earlier phases of treatment in combination with chemotherapy agents. In the R/R setting, our expanding understanding of HL's various mechanisms of immune evasion and treatment resistance has spurred a growing number of rationally designed combination trials. Beyond BV and PD-1 blockade, other novel therapies have demonstrated encouraging preliminary results, including targeted agents, like the CD25 antibody-drug conjugate ADCT-301, and cellular therapies, including CD30 chimeric antigen receptor T cells and Epstein-Barr virus (EBV)-directed cytotoxic T cells. These trials, coupled with the rapid development of prognostic and predictive biomarkers, should drive additional breakthroughs that promise safer and more effective therapies for patients with HL in the future.

SUBMITTER: Merryman RW 

PROVIDER: S-EPMC6913426 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel agents and immune invasion in Hodgkin lymphoma.

Merryman Reid W RW   LaCasce Ann A  

Hematology. American Society of Hematology. Education Program 20191201 1


The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, these agents are currently being tested in earlier phases of treatment in combination with chemotherapy agents. In the R/R setting, our expanding understanding of HL's various mechanisms of immune evasi  ...[more]

Similar Datasets

| S-EPMC4588185 | biostudies-literature
| S-EPMC9820976 | biostudies-literature
| S-EPMC9344040 | biostudies-literature
| S-EPMC5572135 | biostudies-other
| S-EPMC6745954 | biostudies-literature
| S-EPMC7593851 | biostudies-literature
| S-EPMC3534167 | biostudies-other
| S-EPMC5994413 | biostudies-literature
| S-EPMC5502768 | biostudies-literature
| S-EPMC8882667 | biostudies-literature